PROGYNY, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.04 USD | -1.42% |
|
-2.02% | -13.82% |
| Sales 2024 * | 1.3B 104B | Sales 2025 * | 1.57B 125B | Capitalization | 3.08B 247B |
|---|---|---|---|---|---|
| Net income 2024 * | 70M 5.6B | Net income 2025 * | 105M 8.41B | EV / Sales 2024 * | 2.17 x |
| Net cash position 2024 * | 263M 21.05B | Net cash position 2025 * | 481M 38.52B | EV / Sales 2025 * | 1.66 x |
| P/E ratio 2024 * |
46.9
x | P/E ratio 2025 * |
31.7
x | Employees | 565 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.31% |
More Fundamentals
* Assessed data
More news
Latest transcript on Progyny, Inc.
More recommendations
More press releases
| 1 day | -1.42% | ||
| 1 week | -2.02% | ||
| Current month | -16.02% | ||
| 1 month | -13.50% | ||
| 3 months | -14.99% | ||
| 6 months | +6.62% | ||
| Current year | -13.82% |
1 week
31.99
33.36
1 month
31.8038.98
Current year
31.8042.08
1 year
29.4444.95
3 years
25.6768.32
5 years
13.2968.32
10 years
13.2968.32
| Managers | Title | Age | Since |
|---|---|---|---|
Peter Anevski
CEO | Chief Executive Officer | 56 | 31/12/16 |
Michael Sturmer
PSD | President | 47 | 28/02/21 |
Mark Livingston
DFI | Director of Finance/CFO | 58 | 30/04/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Beth Seidenberg
BRD | Director/Board Member | 67 | 30/04/10 |
Kevin Gordon
BRD | Director/Board Member | 61 | 30/09/19 |
Norman Payson
BRD | Director/Board Member | 75 | 15/12/16 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.12% | 509 M€ | -.--% | ||
| 0.10% | 45 M€ | +0.20% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 32.04 | -1.42% | 583,458 |
| 25/04/24 | 32.5 | -0.31% | 588,703 |
| 24/04/24 | 32.6 | +0.62% | 759,162 |
| 23/04/24 | 32.4 | -2.00% | 625,285 |
| 22/04/24 | 33.06 | +1.10% | 663,390 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Progyny, Inc. is a benefit management company. The Company specializes in fertility and family building benefits solutions in the United States. The Companyâs clients include various employers across an array of industries. It has contracts to provide coverage to approximately 6.4 million employees and their partners (known as members). The Company provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a memberâs full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. It provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.
Sector
Managed Healthcare
Calendar
08/05/2024
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
32.04
USD
Average target price
46.9
USD
Spread / Average Target
+46.38%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.82% | 3.08B | |
| +13.93% | 125B | |
| +18.37% | 101B | |
| -0.28% | 39.69B | |
| -33.18% | 36.86B | |
| -5.28% | 20.05B | |
| -39.49% | 993M | |
| -28.58% | 337M |
- Stock Market
- Equities
- PGNY Stock
